Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens

Subunit viral vaccines are typically not as efficient as live attenuated or inactivated vaccines at inducing protective immune responses. This paper describes an alternative ‘biomimetic’ technology; whereby viral antigens were formulated around a polymeric shell in a rationally arranged fashion with...

Full description

Bibliographic Details
Main Authors: Riitho, Victor, Walters, Adam A., Somavarapu, Satyanarayana, Lamp, Benjamin, Rümenapf, Till, Krey, Thomas, Rey, Felix A., Oviedo-Orta, Ernesto, Stewart, Graham R., Locker, Nicolas, Steinbach, Falko, Graham, Simon P.
Format: Journal Article
Language:Inglés
Published: Springer 2017
Subjects:
Online Access:https://hdl.handle.net/10568/129303
_version_ 1855518395964850176
author Riitho, Victor
Walters, Adam A.
Somavarapu, Satyanarayana
Lamp, Benjamin
Rümenapf, Till
Krey, Thomas
Rey, Felix A.
Oviedo-Orta, Ernesto
Stewart, Graham R.
Locker, Nicolas
Steinbach, Falko
Graham, Simon P.
author_browse Graham, Simon P.
Krey, Thomas
Lamp, Benjamin
Locker, Nicolas
Oviedo-Orta, Ernesto
Rey, Felix A.
Riitho, Victor
Rümenapf, Till
Somavarapu, Satyanarayana
Steinbach, Falko
Stewart, Graham R.
Walters, Adam A.
author_facet Riitho, Victor
Walters, Adam A.
Somavarapu, Satyanarayana
Lamp, Benjamin
Rümenapf, Till
Krey, Thomas
Rey, Felix A.
Oviedo-Orta, Ernesto
Stewart, Graham R.
Locker, Nicolas
Steinbach, Falko
Graham, Simon P.
author_sort Riitho, Victor
collection Repository of Agricultural Research Outputs (CGSpace)
description Subunit viral vaccines are typically not as efficient as live attenuated or inactivated vaccines at inducing protective immune responses. This paper describes an alternative ‘biomimetic’ technology; whereby viral antigens were formulated around a polymeric shell in a rationally arranged fashion with a surface glycoprotein coated on to the surface and non-structural antigen and adjuvant encapsulated. We evaluated this model using BVDV E2 and NS3 proteins formulated in poly-(D, L-lactic-co-glycolic acid) (PLGA) nanoparticles adjuvanted with polyinosinic:polycytidylic acid (poly(I:C) as an adjuvant (Vaccine-NP). This Vaccine-NP was compared to ovalbumin and poly(I:C) formulated in a similar manner (Control-NP) and a commercial adjuvanted inactivated BVDV vaccine (IAV), all inoculated subcutaneously and boosted prior to BVDV-1 challenge. Significant virus-neutralizing activity, and E2 and NS3 specific antibodies were observed in both Vaccine-NP and IAV groups following the booster immunisation. IFN-γ responses were observed in ex vivo PBMC stimulated with E2 and NS3 proteins in both vaccinated groups. We observed that the protection afforded by the particulate vaccine was comparable to the licenced IAV formulation. In conclusion, the biomimetic particulates showed a promising immunogenicity and efficacy profile that may be improved by virtue of being a customisable mode of delivery.
format Journal Article
id CGSpace129303
institution CGIAR Consortium
language Inglés
publishDate 2017
publishDateRange 2017
publishDateSort 2017
publisher Springer
publisherStr Springer
record_format dspace
spelling CGSpace1293032025-12-08T09:54:28Z Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens Riitho, Victor Walters, Adam A. Somavarapu, Satyanarayana Lamp, Benjamin Rümenapf, Till Krey, Thomas Rey, Felix A. Oviedo-Orta, Ernesto Stewart, Graham R. Locker, Nicolas Steinbach, Falko Graham, Simon P. evaluation antigens design formulation Subunit viral vaccines are typically not as efficient as live attenuated or inactivated vaccines at inducing protective immune responses. This paper describes an alternative ‘biomimetic’ technology; whereby viral antigens were formulated around a polymeric shell in a rationally arranged fashion with a surface glycoprotein coated on to the surface and non-structural antigen and adjuvant encapsulated. We evaluated this model using BVDV E2 and NS3 proteins formulated in poly-(D, L-lactic-co-glycolic acid) (PLGA) nanoparticles adjuvanted with polyinosinic:polycytidylic acid (poly(I:C) as an adjuvant (Vaccine-NP). This Vaccine-NP was compared to ovalbumin and poly(I:C) formulated in a similar manner (Control-NP) and a commercial adjuvanted inactivated BVDV vaccine (IAV), all inoculated subcutaneously and boosted prior to BVDV-1 challenge. Significant virus-neutralizing activity, and E2 and NS3 specific antibodies were observed in both Vaccine-NP and IAV groups following the booster immunisation. IFN-γ responses were observed in ex vivo PBMC stimulated with E2 and NS3 proteins in both vaccinated groups. We observed that the protection afforded by the particulate vaccine was comparable to the licenced IAV formulation. In conclusion, the biomimetic particulates showed a promising immunogenicity and efficacy profile that may be improved by virtue of being a customisable mode of delivery. 2017-10-23 2023-03-10T14:33:05Z 2023-03-10T14:33:05Z Journal Article https://hdl.handle.net/10568/129303 en Open Access Springer Riitho, Victor; Walters, Adam A.; Somavarapu, Satyanarayana; Lamp, Benjamin; Rümenapf, Till; Krey, Thomas; Rey, Felix A.; Oviedo-Orta, Ernesto; Stewart, Graham R.; Locker, Nicolas; Steinbach, Falko; Graham, Simon P. 2017. Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens. Scientific Reports 7:
spellingShingle evaluation
antigens
design
formulation
Riitho, Victor
Walters, Adam A.
Somavarapu, Satyanarayana
Lamp, Benjamin
Rümenapf, Till
Krey, Thomas
Rey, Felix A.
Oviedo-Orta, Ernesto
Stewart, Graham R.
Locker, Nicolas
Steinbach, Falko
Graham, Simon P.
Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens
title Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens
title_full Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens
title_fullStr Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens
title_full_unstemmed Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens
title_short Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens
title_sort design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens
topic evaluation
antigens
design
formulation
url https://hdl.handle.net/10568/129303
work_keys_str_mv AT riithovictor designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT waltersadama designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT somavarapusatyanarayana designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT lampbenjamin designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT rumenapftill designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT kreythomas designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT reyfelixa designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT oviedoortaernesto designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT stewartgrahamr designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT lockernicolas designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT steinbachfalko designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens
AT grahamsimonp designandevaluationoftheimmunogenicityandefficacyofabiomimeticparticulateformulationofviralantigens